OBN Invites Life Science Leaders to Celebrate 20 Years of BioTrinity
March 3, 2026 – Other, Pharmaceutical – BioTrinity 2026, OBN, conferences and events, life sciences, research and development
- Featuring keynotes from: Steve Bates, Executive Chair at the Office for Life Sciences, Lawrence Tallon, CEO at the MHRA & Maria Koufali, Life Sciences Industry Director at the NIHR, click here for the full lineup
- Expanded format in 2026 to welcome over 850 delegates with 120+ showcase presentations, a dedicated one-day international market showcase, and a focus on alternative funding routes
- Two-day life science conference taking place 14th-15th April at 133 Houndsditch (London, UK).
3 March 2026 — Oxford and London, UK — OBN (UK) Ltd., the membership organisation whose mission is to catalyse success in the life science industry, is pleased to invite R&D companies, professionals and investors from across the life science and pharma industries to attend BioTrinity 2026 on 14th-15th April at 133 Houndsditch, London, UK.
BioTrinity is OBN’s flagship life science conference, designed to unite key industry stakeholders, foster collaboration and catalyse growth. Since first launching in 2006, BioTrinity has grown to one of the UK’s leading life science events, with the 20th edition expected to welcome over 850 attendees, including: early and emerging life science R&D companies, investors, academics, large pharma, government, industry service providers, and international life science clusters.
This year, BioTrinity 2026 will offer a significantly expanded programme of presentations, providing a platform for R&D companies from academia through to Series B & Big Pharma to showcase their latest research breakthrough and goals for fundraising, collaboration, licensing and partnerships. Alongside this, the 2026 event will also host a dedicated one-day ‘international market showcase’, with leading life science clusters so far including the US, Switzerland, Canada & Flanders, demonstrating how companies can drive growth in markets worldwide.
In addition to the presentation tracks running throughout the event, BioTrinity will also offer:
- New for 2026, a focus on unlocking access to alternative sources of funding
- Sponsors’ exhibition hall, featuring a broad selection of life science service providers & supporters
- Dedicated partnering system and space for private 1:1 partnering meetings, powered by partneringONE
- A new ‘mentor match-making lunch’ to help early-stage founders and CEOs connect with experienced leaders
- An increased big pharma presence
Stuart Rose, CEO of OBN, commented: “It is a privilege this year to mark 20 years of BioTrinity, and celebrate the unique position this conference holds in catalysing growth by uniting decision-makers from all corners of the life science sector. Building on this milestone, we are pleased to be significantly expanding the scope of BioTrinity with several new launches, including our international market showcase – designed to represent the increasingly global nature of life sciences by providing a hub for companies to explore the opportunities available in clusters around the world. My thanks go to our dedicated team, and to our partners, sponsors and members, who together have made two decades of BioTrinity so special.”
To access the full event programme of speakers and sessions and to register, please visit: https://obn.glueup.com/event/biotrinity-2026-140616/
About OBN
OBN is a life sciences network, focused on catalysing growth across the industry. Our 540+ member companies are located throughout the UK and benefit from our events, networking, partnering, purchasing, advising and advocacy activities. Visit: www.obn.org.uk
